McCoy S E
Laser, Skin and Vein Clinic, North Adelaide, South Australia.
Lasers Surg Med. 1997;21(4):329-40. doi: 10.1002/(sici)1096-9101(1997)21:4<329::aid-lsm4>3.0.co;2-s.
Various yellow light lasers have been used over the past decade in an attempt to eradicate facial telangiectasia. Based on their power output, spot size, and pulsing characteristics, these lasers belong to one of two categories that exist at either end of a spectrum--high power, short pulse, and large spot size, or low power, long exposure, and small spot size. The copper bromide laser clearly belongs in the latter group, but with higher available power than most other lasers in this group, it exists further along the spectrum toward the region in which the laser parameters might be considered closer to theoretical ideals for treating certain cutaneous vascular pathologies. The objective of this study was to ascertain the role and efficacy of the copper bromide laser on treatment of a variety of facial telangiectasia.
STUDY DESIGN/MATERIALS AND METHODS: A total of 570 patients with facial telangiectasia of different diameters and on different regions of the face were treated with the copper bromide laser one or more times and followed up over 5 years.
More than 75% clearance was achieved in 70% patients, 50-75% clearance in 17.4% patients, and < 50% clearance in 12.6% patients. Poor results were correlated with anatomical location on the nasal alae and nasal tip and also with vessel size. Very small (< 100 microns) and very large (> 300 microns) vessels did not respond as well as vessels in the 100-300-micron diameter group. Very large vessels responded better to a combination of sclerotherapy and laser treatment. There were no reported long-term adverse effects.
The copper bromide laser is a safe and effective modality for the treatment of the majority of facial telangiectasia. It is less suited to treating very small vessel lesions such as diffuse erythema, and conversely very large vessels as well as those of the nasal alae. These latter two groups respond better and more permanently to combined sclerotherapy and laser treatment.
在过去十年中,人们使用了各种黄光激光来试图消除面部毛细血管扩张。根据其功率输出、光斑大小和脉冲特性,这些激光属于光谱两端存在的两类之一——高功率、短脉冲和大光斑大小,或低功率、长时间曝光和小光斑大小。溴化铜激光显然属于后一组,但与该组中的大多数其他激光相比,其可用功率更高,它在光谱上更靠近激光参数可能被认为更接近治疗某些皮肤血管病变的理论理想区域。本研究的目的是确定溴化铜激光在治疗各种面部毛细血管扩张中的作用和疗效。
研究设计/材料与方法:总共570例面部不同直径和不同部位出现毛细血管扩张的患者接受了一次或多次溴化铜激光治疗,并进行了5年的随访。
70%的患者实现了超过75%的清除率,17.4%的患者实现了50 - 75%的清除率,12.6%的患者清除率小于50%。治疗效果不佳与鼻翼和鼻尖的解剖位置以及血管大小有关。非常小(<100微米)和非常大(>300微米)的血管反应不如直径在100 - 300微米组的血管。非常大的血管对硬化疗法和激光治疗联合使用反应更好。未报告有长期不良反应。
溴化铜激光是治疗大多数面部毛细血管扩张的一种安全有效的方式。它不太适合治疗非常小的血管病变,如弥漫性红斑,相反,对于非常大的血管以及鼻翼的血管也不太适用。后两组对硬化疗法和激光治疗联合使用反应更好且更持久。